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Novel GnRH I and II analogues were designed and synthesized by Solid Phase Peptides Synthesis (SPPS), since GnRH has 
antiproliferative property, but poor metabolic stability. To rationalize synthetic difficulties, molecular dynamics simulations were 
performed, showing the conformational behavior of three derivatives. Among the two peptidomimetics series (Ie,f and IIe,f , GnRH I 10 
and GnRH II analogues respectively) several compounds (Id-f and IIc-e) showed a significant binding affinity. In particular, derivative 
Ie has an increased metabolic stability with respect to the physiological ligand (Ie t1/2= 3.96 h versus GnRH I t1/2 = 2.63 h). 
 
Introduction 
The steroid hormones, estrogens and androgens, are key 15 
drivers of several types of cancer, such as that of prostate, one 
of the most common invasive cancer in men. At present, 
hormone therapies demonstrate success on this type of tumor, 
highlighting its dependence on gonadal. Although most 
prostate tumors initially respond to hormone therapy1 by 20 
inhibition of their growth, others stopped respond to the 
treatment, indicating the need to develop novel therapeutic 
approches.  
Prevoius research2 has shown that GnRHs (GnRH I and II) 
and their receptors are expressed in cancer cells and the 25 
activation of GnRH receptors negatively regulates their 
proliferation for instance in prostate cancer. 
GnRH I is a hypotalamic decapeptide (pGlu1-His2-Trp3-Ser4-
Tyr5-Gly6-Leu7-Arg8-Pro9-Gly10-NH2, Figure 1) able to bind 
specific receptors on pituitary gonadotrope cells to modulate 30 
the synthesis and secretion of gonadotropins, luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH)3 that, 
in turn, regulate gonadal steroidogenesis and gametogenesis. 
Numerous experimental data showed an overexpression of 
GnRH I and its receptor in human malignant tumors, such as 35 
prostate, breast, uterine, ovarian cancers and also in the non- 
reproductive ones.  
In addition to its direct action on cancer cells, GnRH I affect 
their growth by triggering the secretion of steroid hormones 
from the gonads.  40 
Moreover, the antiproliferative activity of GnRH analogues 
have been proven through several studies.3 
Furthermore a second form of GnRH (GnRH II, Chart 1) has 
been identified in humans.4 It is a decapeptide, encoded by a 
diverse gene, differing from the classical GnRH (GnRH I, 45 
Chart 1) in three amino acids . The ability of GnRH II to 
inhibit selectively the growth of cancer cells has been recently 
discovered.2 This occurs through a different mechanism of 
action than the classic GnRH agonists one, which involves the 
suppression of secretion of pituitary hormones and hence 50 
production of sex hormones1 
Although GnRH antagonists (which can be considered as a  
 
 
new generation of male and female contraceptives with add-55 
back gonadal steroids3) have found increasing application in the 
therapy of prostate cancer,5a however recent studies on the 
activation of the receptors by GnRH agonists also showed a 
significant reduction of the proliferation of prostate cancer 
cells both in vitro and in vivo5b (when inoculated into nude 60 
mice). Moreover, GnRH agonists are able to decrease the 
invasive behavior6,7 of androgen-dependent and independent 
prostate cancer cells,8-10 although in this case the administration 
may be used as an adjuvant therapy. Preliminary experimental 
data indicate that GnRH agonists increase expression of genes 65 
related to apoptosis and develop a cytostatic action rather than 
cytotoxic.11 They can sensitize prostate cancer cells to the 
activity of pro-apoptotic agents, which can be considered as a 
possible targeted therapy, in combination with traditional 
chemotherapy, with the aim to increase antiproliferative 70 
activity and possibly reduce undesired side-effects .12 
As many hormones of peptidic nature, GnRH I and II are 
highly flexible molecules, existing in solution as a mixture of 
different conformers in equilibrium. GnRH is characterized by 
the presence of a β-turn in position Gly6-Leu7, as proven 75 
through the substitution of Gly6 13 with D-amino acids, Leu7 
with N-methyl-leucine and the introduction of a lactam 
bridge, able to force the angles Ψ of Gly6 and Φ of Leu7 14 
favoring a β-turn conformation.15 All these modifications 
resulted to give the maintenance or improvement of biological 80 
activity. 
 
 
 
 85 
 
 
 
 
 90 
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 5 
 
 
 
 
 10 
Figure 1.16 Schematic representation of GnRH I in the folded 
conformation in which it is bound to the GnRH pituitary receptor. 
 
Since the β-turn present in the GnRH-I and II seems to be 
essential for the biological activity of these hormones, a large 15 
number of cyclic peptides related to GnRH-I have been 
designed to maintain this property. 
 
 
 20 
 
 
 
 
 25 
 
 
 
 
 30 
 
 
 
 
 35 
 
 
 
 
 40 
 
 
 
 
 45 
 
 
 
 
Chart 1 50 
 
The replacement of the glycine residue at position 6 has been 
shown to stabilize of the folded conformation and decreases 
the metabolic clearance.17 All the analogues, agonists and 
antagonists, have been synthesized with this structural 55 
modification (for instance, among the agonists, Leuprolide has 
a D-Leu residue,8a while Goreselin a D-Ser18-20 at position 6). 
In order to identify new potential peptidomimetic analogues 
of GnRH, with potential biological activity, we focused our 
attention on the synthesis of two novel series (I and II, GnRH 60 
I and GnRH II analogues, respectively) by SPPS 
methodology.21,22 We considered the introduction of non 
natural amino acids at position 6, such as those with cycled 
structures, which are known to favour the interaction between 
the receptor and the ligand, because of their β-turn inducer 65 
nature (I-II a-e, Table 1). Of note, the steric hindrance and the 
minor peptidic character of the novel analogues could reduce 
the metabolic cleavage, occurring at position 6-7, and increase 
their biological half-life.23-24 
 70 
Table 1. GnRH I and II analogues I-II a-e. 
 
 
Furthermore in attempt to improve the metabolic stability, few 
other derivatives (Table 2) of GnRHI (I f-g) and GnRH II (II 75 
f-g) have been prepared, using Cptd (3-carboxymethyl-1-
phenyl-1,3,8-triazaspiro [4.5]decan-4-one. The introduction of 
this latter could reduce the peptidic character of the new 
derivatives. The Cptd moiety replaces a variable number of 
amino acids in the GnRH structure, in particular in 80 
compounds I-IIf it has approximately the same length of the 
three amino acids replaced. Instead, compounds I-IIg are 
shorter than the natural GnRH.  
 
This paper describes the synthesis of compounds I-II a-g, 85 
molecular dynamics simulations performed on some of them, 
to explain some synthetic problems, as well as the human 
GnRH binding assay data. Finally, preliminary metabolic 
stability tests of the most interesting compounds are also 
reported. 90 
 
 
 
Analogue 
Non 
natural 
aa at 
position 
6 
Name 
Chemical 
Structure 
I-IIa L-Pip-OH 
2S-piperidine-2-carboxylic 
acid N
H
OH
O  
I-IIb D-Pip-OH 
2R-piperidine-2-carboxylic 
acid N
H
OH
O  
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OH 
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Table 2. GnRH I and II analogues I-II f-g. 
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 15 
 
 
 
 
Chemistry 20 
Solid Phase Peptides Synthesis (SPPS) of GnRH I and 
GnRH II analogues 
 
The peptidomimetics were synthesized by the general SPPS 
procedure reported in Scheme 1. 25 
Series I a,b,d-g and II a-g were obtained on solid phase using the 
resin Rink amide MBHA (4-methyl-benzhydryl-hydroxy-
ammine), that provides peptides carboxy amidated, and Fmoc 
(fluorenyl-methoxycarbonyl group) to protect the N-terminal end. 
The support consists in a modified Rink amide linker, bound 30 
through a Norleucine residue to the MBHA resin. Glycine, 
Proline, Leucine and  Pyroglutamic acid did not require the use of 
protecting groups.  
Peptide synthesis begins with deprotection of Fmoc group from 
the Rink Amide MBHA resin (activation of the resin) using 35 
Piperidine  in DMF. 
In coupling reaction for amino acids and non natural amino 
acids (L-Pip-OH, D-Pip-OH, AC4C-OH, AC5C-OH, AC6C-OH 
and pGlu), TBTU and HOBt were used as coupling reagent in 
alkaline conditions (DIEA).This reactive is able to generate a 40 
benzotriazole ester, characterized by excellent activity and 
chiral stability. Instead, in coupling reaction with  Cptd, 
HATU was used as coupling reagent, because of the required 
stronger conditions, due to the steric hindrance of the compound. 
The synthesis occurred very quickly, without side reactions. 45 
The first amino acid Glycine was attached to the resin by the 
C-terminal end, while the N-terminal end was deprotected 
before the following coupling.  
After the complete synthesis, the peptide was washed with 
DCM and cleaved with TFA and a scavenger cocktail. The 50 
latter consists in a mixture of thioanisole, to accelerate the 
removal of some protecting groups in TFA, phenol, and 
triisopropylsilane (TIS), very effective in the case of peptides 
containing Arg (Pmc) and Trp (Boc) and for the elimination of 
free cations, formed by the cleavage of Trt resin and Rink 55 
Amide linker. Finally, peptides were purified by HPLC. All 
the designed compounds were obtained according to this 
scheme with the exception of Ic, since the shorter derivative 
D-Ic, precursor of Ic lacking of pyroglutamic acid (pGlu), was 
achieved. 60 
 
 
 
 
 65 
 
 
 
 
 70 
 
 
 
 
 75 
 
 
 
 
 80 
 
 
 
Scheme 1. SPPS procedure for the synthesis of GnRH I and GnRH II 
analogues. a) 20% piperidine in DMF; b) Fmoc-aa, TBTU, HOBt, DIEA, 85 
DMF (for natural Fmoc amino acids L-Pip-OH, D-Pip-OH, AC4C-OH, 
AC5C-OH, AC6C-OH and pGlu); b’) HATU, DMF (for Cptd); c) TFA, 
water, phenol, thioanisole, triisopropylsilane. 
 
 90 
Molecular Dynamics Simulations 
 
Molecular dynamics (MD) simulations were performed on the 
nonapeptide His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly 1 
(derivative of GnRH I without pGlu) and derivatives D-Ic, D-95 
Id, D-Ie (Figure 2), which are the corresponding analogues of 
products Ic, Id, Ie, lacking pGlu. The MD simulations were 
used to properly compare the behaviour of these analogues in 
order to understand the unsuccessful coupling among pGlu 
and the nonapeptide D-Ic, last intermediate of Ic synthesis. 100 
The N-terminus residue was protected as ACE (acetyl), while 
the C-terminus as NME (N-methyl). 
All the calculations were carried out using the SANDER 
module of the AMBER 10 package25 along with the ff03 force 
field for 1 and the general amber force field (gaff) for D-Ic, 105 
D-Id, D-Ie and RESP atomic charges. The TIP3P model26 was 
employed to explicitely represent water molecules. The 
polypeptides were immersed in a box containing about 1300 
water molecules. At first, the energy of the water molecules 
was minimized, keeping the atoms of the polypeptides frozen.  110 
 
 
 
 
 115 
 
 
Analogue Sequence 
If pE-H-W-Cptd-L-R-P-G-NH2 
Ig pE-H- Cptd-R-P-G-NH2 
IIf pE-H-W-Cptd-W-Y-P-G-NH2 
IIg pE-H-Cptd-Y-P-G-NH2 
N
H
N
N
O
O
OH
Cptd 
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Figure 2. Nonapeptidic analogue of GnRH I and its derivatives D-Ic, 
D-Id, D-Ie. 
 55 
Then, a minimization of the whole system was performed by 
setting a convergence criterion on the gradient of 10-4 kcal 
mol-1 Å-1. Prior to starting the MD simulations, the system 
was equilibrated for 40 ps at 300 K in isocore conditions 
(NVT). Subsequently, 5 ns of MD simulations in isothermal-60 
isobaric ensemble were carried out at 300 K with a 2 fs time-
step (NPT). In the production runs, the systems were 
performed in periodic boundary conditions. Van der Waals and 
short-range electrostatic interactions were estimated within a 8 Å 
cutoff. SHAKE algorithm27 was applied to all bonds involving 65 
hydrogen atoms. VMD 1.8.7 was used for molecular 
visualization and for animating trajectory data.28
 
 
 
 70 
 
 
 
 
 75 
 
 
 
 
 80 
 
 
 
 
 85 
 
 
Figure 3. History of d1 (left) and d2 (right) in the MD simulation 
starting from a linear arrangement of peptides D-Ic-e, from top to 
bottom. 90 
 
Particular attention was focussed on the possibility of -turn 
formation. In fact, it is known that the presence of a -turn in 
position Gly6-Leu7 of GnRH I is essential for biological 
activity.  During the MD simulation, in the case of 1, the 95 
presence of two -turns, already known in literature was 
detected: the first one between Tyr and Arg, the second one 
between Ser and Leu.23 Previous structure-function studies 
showed that the substitution of Tyr to eliminate the postulated 
-II turn with Arg led to a reduction in the binding affinity, 100 
while the substitution of Leu to remove the envisaged H bond 
between the C=O of Ser and the NH of Leu did not reduce 
activity. So, MD trajectories were examined in order to assess 
the maintenance of these turns and the distances d1 between 
C(Tyr)-N(Arg) and d2 between C(Ser)-N(Leu). In Figure 3 the 105 
trajectories of d1 and d2 for peptides D-Ic, D-Id and D-Ie are 
shown, respectively, from top to bottom. In the case of D-Ic, 
the -II turn between Tyr and Arg is present during about all 
the MD simulation, while the other one (Ser-Leu) tries to form 
at the beginning of the simulation but breaks almost 110 
immediately and C and N atoms keep themselves at a distance 
of about 6 Å. On the contrary, in the case of  peptide D-Id, the 
Tyr-Arg -turn never forms and the distance between C and N 
is about 5 Å, while the Ser-Leu -turn is present for about all 
the simulation. Finally, as expected on the base of the 115 
geometry of tetrahedral C atom of hexacyclic ring, peptide D-
Ie shows the most similar behaviour to the reference 
compound 1. In fact, the presence of both -turn was detected 
during the simulation.  
N
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The different conformational preferences of D-Ic, and, in 
particular, the complete lack of the -turn between Ser-Leu, 
present in all the other peptides, seem to explain the synthetic 
difficulties found to bind the last monomer to its polypeptidic 
chain. More precisely, the absence of the second β-turn is 5 
supposed to lead to an unfavourable orientation of the peptidic 
chain for introducing the N-terminal amino acid. 
Moreover, the MD simulations show that the peptidomimetic D-Ie 
presents the most similar behavior to the reference.  
 10 
 
Biological evaluation  
 
Compounds I a,b,d-g, D-Ic, IIa-g were pharmacologically 
evaluated for their ability to bind to GnRH receptor. Before 15 
determining the binding affinities of these compounds their 
ability to inhibit specific binding of [125I]-DTyr6-His5-GnRH 
to human type I GnRH receptor was tested, at the single 
concentration of 500 nM, under equilibrium conditions 
(Figure 4), since it is known that GnRH II binds the type I 20 
GnRH receptor in different cell lines (e.g. prostate and 
ovarian cancer cells)2. The  Leuprolide (500 nM) was used as 
a reference compound. The radioligand binding experiments 
were performed on membrane homogenates from HEK 293 
cells stably expressing human GnRH receptor. In this initial 25 
screening compounds with poor ability to inhibit [125I]-DTyr6-
His5-GnRH specific binding were not further 
pharmacologically evaluated. Binding affinities (-LogIC50) for 
the human GnRH receptor were determined for the most 
interesting compounds Id-f and IIc-e (Table 3) in radioligand 30 
competition binding experiments.  
 
 
 
 35 
 
 
 
 
 40 
 
 
 
 
 45 
 
 
 
 
 50 
 
 
 
 
Figure 4. Inhibition of [125I]-DTyr6-His5-GnRH specific binding by the 55 
GnRH analogues on membrane homogenates from HEK 293 cells stably 
expressing the human type I GnRH receptor. The bars represent the % 
inhibition of radioligand specific binding by 500 nM of the GnRH 
analogues, I a,b,d-g, D-Ic, II a-g (or Leuprolide as control), determined 
from 2-3 experiments (with their means and S.E.). 60 
 
 
 
 
 65 
Table 3. Binding affinity values of GnRH analogues Id-f, IIc-e. 
 
Compound -LogIC50± S.E (N=2-3) 
        Id                              6.23 ± 0.03 
Ie 6.26 ± 0.26 
If 6.14 ± 0.28 
IIc 6.72 ± 0.28 
IId 6.55 ± 0.13 
IIe 6.39 ± 0.40 
Leuprolide 9.54 ± 0.31 
 
Competition of [125I-D-Tyr6, His5] GnRH specific binding by 
increasing concentrations of the GnRH analogues Id-f, IIc-e  was 70 
performed on membrane homogenates from HEK 293 cells stably 
expressing the human type I GnRH receptor. The mean values and 
S.E. are shown from 2–3 different experiments. The data were fit to a 
one site competition model by nonlinear regression and the -LogIC50 
values were determined as described in the Experimetal part. 75 
Compounds Id-f and IIc-e bound to human type I GnRH 
receptor in a concentration dependent manner (Figure 5). 
 
 
 80 
 
 
 
 
 85 
 
 
 
 
 90 
 
 
 
 
 95 
 
 
 
 
 100 
 
 
 
 
 105 
 
 
 
 
Figure 5. Competition binding isotherms of GnRH analogues Id-f, IIc-e to 110 
human type I GnRH receptor. 
 
Since GnRH II binds the human type I GnRH receptor mediating the 
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antiproliferative activity2, compound IIe was choosen as reference 
for a colorimetric MTT assay. The latter is based on the ability of 
living cells to reduce the yellow MTT to purple formazan and it is 
widely used to quantitate cell viability and cytotoxicity of various 
drugs. The results indicate that similar to Leuprolide, the compound 5 
IIe decreased the growth of HEK 293 cells expressing the type I 
GnRH receptor (Figure 6). However, the antiproliferative efficacy of 
compound IIe (as determined by its absorbance ratio versus the 
control) was smaller than that of Leuprolide (Figure 6), in agreement 
with the ability of this compound to bind to type I GnRH receptor 10 
although with a smaller affinity than that of Leuprolide (Figure 5). 
 
 
 
 15 
 
 
 
 
 20 
 
 
 
 
 25 
 
 
 
 
 30 
 
Figure 6. Effect of compound IIe on cell proliferation. Antiproliferative 
effect of IIe compound and Leuprolide were determined by their abilities to 
inhibit the growth of HEK 293 cells stably expressing the type 1 GnRH 
receptor following continuous 4 days exposure of cells to drugs. The 35 
antiproliferative effect was estimated by the MTT assay, as described in the 
Experimental section. The antiproliferative efficacy of IIe was determined by 
the % ratio of its normalized absorbance value versus that of the untreated cells 
(control). Normalization was performed by subtracting the absorbance values 
of wells containing only medium (control-blank) from those of sample and 40 
control. Each bar represents the mean ± standards error value for 2 
independent experiments. 
 
Metabolic stability  
 45 
To evaluate the metabolic stability of GnRH I, GnRH II and their 
analogues Ie and IIe, that show the most interesting biological 
results, a preliminary assay using rat plasma was performed. 
The results (Figure 7) showed that in compounds Ie and IIe the 
substitution of Gly6 with the non natural amino acid AC6C-OH 50 
results to improve their stability by 15-20 % after four hours 
when compared to GnRH I and GnRH II, respectively. 
In particular, product Ie showed a significant increase of half 
life time with  respect to GnRHI (Ie t1/2= 3.96 h versus GnRHI 
t1/2 = 2.63 h) (For further detail see ESI). 55 
 
 
Figure 7. Metabolic stability of GnRHI-II and their derivatives Ie and 
IIe. 
 60 
Conclusions 
 
Our research aimed to synthesise novel peptidomimetics as 
analogues of GnRH I and II, in order to identify new agonist for 
the type I GnRH receptor with potential antiproliferative 65 
activity. 
All derivatives have been synthesized by solid phase peptide 
synthesis with the exception of Ic. MD simulations, performed 
on peptidomimetics Ic-e deprived of the last residue (D-Ic-e), 
explained the difficulty in the synthetis of Ic, probably due to 70 
a different conformational behaviour of this analogue and in 
particular to the complete lack of the -turn between Ser-Leu, 
present both in D-Id and D-Ie. Moreover, calculations showed 
that D-Ie might have the most similar behaviour to the 
reference compound 1.  75 
The synthesized products were tested in binding assays on human 
type I GnRH receptor. Compounds Id-f and IIc-e exhibited  
considerable binding affinities, supporting the assumption that the 
introduction of β-turn inducers in GnRH I and II structures were 
essential for the binding to GnRH receptor and confirming the 80 
fundamental role of the β-turn presence for the activity. Biological 
data showed that compounds I-IIe may be considered the most 
active in their series (I and II respectively), giving experimental 
support to the modeling hypothesis.  
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Finally, preliminary metabolic stability assays revealed that the 
two derivatives Ie and IIe were more stable than GnRH I and 
GnRH II, due to their reduced peptidic character. These results will 
be useful for the development of novel GnRH analogues with 
improved stabilities and antiproliferative activities. 5 
Experimental Part 
Chemistry 
Resin, Fmoc amino-acids, solvents and reagents were purchased 
from IRIS Biotech GmbH (Schnelldorf, Germany) and were used 
without further purification. The peptides were synthesized 10 
manually using polypropylene syringes (10 mL) with a porous 
polyethylene disc purchased from Grace. The analytical HPLC 
was performed using apparatus Elite La Chrome. The preparative 
HPLC was performed using apparatus Waters 3000 System 
Controller. The spectra of high-resolution ESI-MS were recorded 15 
using a mass spectrometer LTQ-Orbitrap XL. 
General procedure. The synthesis of peptides was performed on 
solid phase starting from 290 mg of Rink amide resin (130 mmol, 
loading: 0.46 mmol /g). 
Swelling. Resin was weighted in a test tube. N-methylpyrrolidone 20 
(NMP, 1 mL for 130 mmol of resin) and dichloromethane (DCM, 
2 mL) were added. The suspension was allowed to sonicate for 2-
3 minutes and then poured into the reactor, washing the tube with 
DCM in order to recover the resin. The liquid was filtered to 
obtain the dry resin. 25 
The Fmoc-protected Rink-amide resin was treated with 20 % 
piperidine in DMF for 5 minutes, then the solution was filtered 
and the resin was treated again with 20% piperidine in DMF for 
15 minutes. After the solution was filtered, the resin was washed 
6 times with DMF. 30 
Coupling. The Fmoc-amino acid (4 equivalents) and non-natural 
amino acids were dissolved in a solution of TBTU / HOBt (0.45 
M in DMF, 4 eq.) Then N,N-diisopropylethylamine (DIEA, 8 eq.) 
was added. The solution was poured into the reactor containing 
the resin and the reaction mixture was left under stirring for 50 35 
minutes, after which the solution was filtered and the resin 
washed with DMF (6 times). Fmoc-Cptd was dissolved in a 
solution of HATU (0.45 M in DMF, 4 eq.) and the followed 
procedure was identical to that described above. Standard 
conditions: 130 mmol of resin, 500 mmol Fmoc-aa, 500 mmol 40 
activator TBTU solution 0,45 M in DMF, DIEA 170 L (1 mol). 
Standard conditions for Cptd: 130 mmol of resin, 250 mmol 
Fmoc-Cptd, 1 mmol activator HATU solution 0.45 M in DMF. 
Fmoc cleavage. A solution of 20 % piperidine in DMF was 
added to the resin. The reaction mixture was left under stirring for 45 
5 minutes, after which the solution was filtered and piperidine 
solution was added to the resin again. The reaction mixture was 
left under stirring for 15 minutes, after which the solution was 
filtered and then the resin washed with DMF (6 times). 
Subsequently, the resin was subjected to a new coupling process 50 
or, if the sequence was finished, washed with DCM for five times 
and dried under nitrogen flow. 
Resin cleavage and purification. A solution of 
TFA/H2O/TIS/thioanisole/phenol (10: 0.5: 0.25: 0.5: 0.75) was 
added to the resin. The reaction mixture was left under magnetic 55 
stirring for 2 h. Then in a test tube it was prepared a mixture of 
tert butylmethyl ether and petroleum ether (1:1), in which the 
contents of the reactor was filtered to allow the precipitation of 
the peptide. The peptide precipitate was washed with t-butyl 
methyl ether and petroleum ether (1:1), centrifuging and 60 
removing the supernatant each time. At the end of the precipitate 
was dissolved in the solution of eluents A (0.1% TFA, water / 
acetonitrile 97:3) and B (0.1% TFA, water/acetonitrile 30:70) 
(1:1). 
Peptide purification. The peptides were purified by preparative 65 
reverse phase HPLC using an appropriate gradient of eluents A 
and B (see above) with a flow of 14 mL/min, and the detection 
was performed at 230 and 280 nm. The purified peptide fractions 
were concentrated under vacuum and to the acqueous was added 
a drop of 1M HCl. The purified peptides were finally freeze-70 
dried. Each final product was checked for purity by analytical 
HPLC (C18 column) using the following gradient: 0-14 min from 
100 % A to 70 %  B (flow 1.0 mL/min). The survey was carried 
out at 230 and 280 nm. 
Synthesis of peptides Ia,b, Id-g and IIa-g. Peptides Ia,b, Id-g, 75 
and IIa-g were synthesized by coupling of Fmoc-Gly-OH (4 eq., 
150 mg) to Rink amide resin (203 mg, 0.64 mmol/g) using TBTU 
/HOBT (4 eq., 1.1 mL, 0.45 M DMF) and DIEA (10 eq., 170 µL).  
The products were obtained following the general procedures for 
synthesis, cleavage and folding described above.  80 
Ia: white solid (7 mg, 4.35 %) MS (ESI) m/z: [M+H]+ Measured 
1235.55; Calculated: 1235.62 
Ib: white solid (5 mg, 3.07 %) MS (ESI) m/z: [M+H]+ Measured 
1236.70; Calculated: 1235.62 
Ic: = not obtained 85 
Id: white solid (7 mg, 4.3 %) MS (ESI) m/z: [M+H]+ Measured 
1236.50; Calculated: 1235.62 
Ie: white solid (21 mg, 12.9%) MS (ESI) m/z: [M+H]+ Measured 
1250.68; Calculated: 1249.64 
If: white solid (20 mg, 20.07%) MS (ESI) m/z: [M+H]+ 90 
Measured:1146.47; Calculated: 1145.59 
Ig: white solid (12.6 mg, 10.8 %) MS (ESI) m/z: [M+H]+ 
Measured:847.22; Calculated: 846.42 
IIa: white solid (68 mg, 40.5%) MS (ESI) m/z: [M+H]+ 
Measured: 1290.80; Calculated: 1289.57  95 
IIb: white solid (75 mg, 44.6%) MS (ESI) m/z: [M+H]+ 
Measured: 1290.80; Calculated: 1289.57  
IIc: white solid (30 mg, 18.07%) MS (ESI) m/z: [M+H]+ 
Measured: 1276.80; Calculated: 1275.56  
IId: white solid (31 mg, 18.4%) MS (ESI) m/z: [M+H]+ 100 
Measured: 1291.60; Calculated: 1290.39; 
IIe: white solid (30 mg, 17.6 %) MS (ESI) m/z: [M+H]+ 
Measured: 1304.60 ; Calculated: 1303.59 
IIf: white solid (19.7 mg, 11.6%) MS (ESI) m/z: [M+H]+ 
Measured:1226.51; Calculated: 1225.55  105 
IIg: white solid (35 mg, 20.6 %) MS (ESI) m/z: [M+H]+ 
Measured 854.60; Calculated: 853.39  
HPLC chromatograms and mass spectra of each compound were 
reported on ESI. 
 110 
Molecular dynamics simulations  
All the calculations were carried out using the SANDER module 
of the AMBER 10 package23 along with the ff03 force field for 1 
and the general amber force field (gaff) for D-I c, D-I d, D-I e and 
RESP atomic charges. The TIP3P model24 was employed to 115 
explicitely represent water molecules. The polypeptides were 
immersed in a box containing about 1300 water molecules. At 
first, the energy of the water molecules was minimized, keeping 
the atoms of the polypeptides frozen. Then, a minimization of 
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the whole system was performed by setting a convergence 
criterion on the gradient of 10-4 kcal mol-1 Å-1. Prior to starting 
the MD simulations, the system was equilibrated for 40 ps at 300 
K in isocore conditions (NVT). Subsequently, 5 ns of MD 
simulations in isothermal-isobaric ensemble were carried out at 5 
300 K with a 2 fs time-step (NPT). In the production runs, the 
systems were performed in periodic boundary conditions. Van 
der Waals and short-range electrostatic interactions were 
estimated within a 8 Å cutoff. SHAKE algorithm25 was applied 
to all bonds involving hydrogen atoms. VMD 1.8.7 was used for 10 
molecular visualization and for animating trajectory data.26 
Binding Studies  
The binding experiments were performed using as radioligand the 
[125I]-DTyr6-His5-GnRH and membrane homogenates from 
human embryonic kidney 293 (HEK 293) cells stably expressing 15 
the GnRH receptor, which were prepared as previously 
described.29 Radioiodination of DTyr6-His5-GnRH was 
performed according to the method of Laimou et al.  [125I]-DTyr6-
His5-GnRH (100,000-120,000 cpm)  was added into membrane 
homogenates and the mixtures were incubated as previously 20 
described.29 Briefly, aliquots of diluted membrane suspensions 
(50 μL) and radioligand were added into tubes containing buffer 
B (25 mM HEPES containing 1 mM CaCl2, 10 mM MgCl2, 0.5% 
BSA, pH 7.4 at 4oC) with or without GnRH-analogues at the 
single concentration of 500 nM or with increasing concentrations 25 
of these analogues (competition binding experiments) in a final 
volume of 0.2 mL. The mixtures were incubated at 4°C for 16-19 
h and then filtered (Brandel cell harvester) through Whatman 
GF/C glass fiber filters, presoaked for 1 h in 0.5 % 
polyethylenimine at 4 °C. The filters were washed four times 30 
with1.5 mL of ice-cold 50 mM Tris-HCl, pH 7.4 at 4 °C. Filters 
were assessed for radioactivity in a gamma counter (LKB Wallac 
1275 minigamma, 80% efficiency). The amount of membranes 
used was adjusted to ensure that the specific binding was always 
equal to or less than 10% of the total concentration of the added 35 
radioligand. Specific [125I]-DTyr6-His5-GnRH binding was 
defined as total binding less nonspecific binding in the presence 
of 1000 nM Triptorelin (Bachem, Germany). Data for 
competition binding were analyzed by nonlinear regression 
analysis, using GraphPad Prism 4.0 (GraphPad Software, San 40 
Diego, CA). The -LogIC50 values were obtained by fitting the 
data from competition studies to a one-site competition model. 
Colorimetric MTT assay  
HEK 293 cells stably expressing the type I GnRH receptor were 
grown in Dulbecco’s modified Eagle’s medium/F-12 (1:1) 45 
(DMEM/F-12) containing 3.15 g/L glucose and 10% bovine calf 
serum at 37°C and 5% CO2. The cells were plated in 96 well 
plates at a density of 2000-2500 cells/well and the plates were 
incubated at 37°C and 5% CO2 for 16 hours.  At the end of the 
incubation, the medium was replaced by DMEM/F-12, containing 50 
3.15 g/L glucose and 5% bovine calf serum, and the cells were 
incubated in a total volume of 100 μL, in the absence (untreated 
cells) or presence of 1μM Leuprolide or 1μM compound IIe, at 
37°C and 5% CO2. Controls included both wells with untreated 
cells (control) and wells containing only medium (control-blank). 55 
The medium with or without peptides was changed every 24 h. 
After 4 days of treatment, the medium was replaced with a fresh 
one without peptides and containing 0.5 mg/mL MTT and the 
plates were incubated for 4 hours at 37°C and 5% CO2. At the 
end of the incubation 100 μL of dimethyl sulfoxide (DMSO) was 60 
added to each well to dissolve the insoluble purple MTT-derived 
formazan crystals into a colored solution. After 1 hour incubation 
at 37°C, the absorbance values at 595 nm were determined on a 
Bio-Rad Elisa microplate reader. The experiments were repeated 
twice in quadruplicates. 65 
Metabolic stability studies  
A solution of the peptide 100 µM in was prepared; then sample 
extraction was performed by adding  
90µL of rat plasma to 10 µL of the solution 100 µM, vortexing 
and incubating at 37.4°C for respectively 0 minutes, 30 minutes, 70 
60 minutes, 4 hours and 24 hours. The proteins were precipitated 
by addition of 100 µL of a solution of perchloric acid 0.1 M; 
samples were left at 0°C for 10 minutes and centrifugated at 1400 
rpm for 10 minutes; to 180 µL of surnatant 180 µL of mobile 
phase were added; the solution is filtered into the analysis vial.  75 
A Surveyor system equipped with a binary pump, autosampler, 
vacuum degasser, and temperature-controlled column 
compartment was used for analyte separation by High 
Performance Liquid Chromatography (HPLC). The mobile phase 
consisted of solvents A (100% water, 0.1% formic acid) and B 80 
(100 % acetonitrile, 0.1 % formic acid). A Synergi 4-POLAR-
RP 80A 150 x 2.00 mm column (Phenomenex) was used at a 
flow rate of 0.2 mL/min. A linear gradient (run time of 20 min) 
from 95% A- 5% B to 15% A- 85% B over 10 min; 15% A- 85% 
B up to 5 min was used for the chromatographic separation of 85 
peptides of interest.  
Mass spectrometry was performed on a LCQ Advantage system 
fitted with a ElectroIonSpray source and a triple quadrupole mass 
spectrometer (Thermofinnigan, Rodano, Milano). The instrument 
was operated in positive ion mode under the following 90 
conditions: IonSpray voltage, 4000 V; source temperature, 
250°C; sheat gas (nitrogen) at 29 (arbitrary units); auxiliary gas 9 
(arbitrary units).  
GnRH I (1182.60 g/mol) was monitored by using the 
multiplereaction monitoring (MRM) transitions of m/z 1182.60 95 
 742.27 + 1011.4 m/z  
GnRH II (1236.70 g/mol) was monitored by using the 
multiplereaction monitoring (MRM) transitions of m/z 1236.70 
 902.27 + 1065.27 m/z  
In vitro peptide stability was determined as a function of time; 100 
using the corresponding MRM transitions for each analyte, the 
peak areas for GnRH I, GnRH II, (peptide concentration of 500 
ng/mL) at t = 0 were set as 100 %. Those peak areas were 
compared to the peak areas derived from samples at t = 30 min, 1 
h, 4 h, 24 h. In addition, analysis of blank samples confirmed the 105 
absence of interference and established the selectivity of the 
assay. The experimental data were analyzed by the exponential 
decay regression model, using GraphPad Prism 4.0 (GraphPad 
Software, San Diego, CA) and the t1/2 values were obtained (ESI). 
Abbreviations 110 
 
Fmoc: Fluorenylmethoxycarbonyl group 
TBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate 
HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 115 
hexafluorophosphate 
HOBt: 1-Hydroxybenzotriazole 
DIEA: N,N-Diisopropylethylamine 
TFA: Trifluoracetic acid 
DMF: N,N-dimethylformamide 120 
DCM: Dichloromethane 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
DMEM: Dulbecco's Modified Eagle Medium 
 125 
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